11 / 27
1. Kudo M
et al
.
Lancet
. 2018;pii:S0140-6736(18)30207–1
REFLECT TRIAL
Primary Endpoint: Kaplan-Meier Estimate of OS
100
90
80
70
60
50
40
30
20
10
0
Time (months)
0
3
6
9
12 15 18 21 24 27 30 33 36 39
42
OS
(95% CI)
HR
(95% CI)
Lenvatinib 13.6 months
(12.1, 14.9)
0.92
(0.79, 1.06)
Sorafenib 12.3 months
(10.4, 13.9)
+++ ++ +
+++
+ + +
++
+ ++++++++++ ++++++++
+
+ + +
++ +
+
+
+ + +
+ ++++ + ++ +++++ + + ++++++++ + + +++ + +++ +++++ + + + + +++++
Overall survival (%)
Number of patients at risk:
Lenvatinib
478 436 374 297 253 207 178 140 102 67 40 21 8 2 0
Sorafenib
476 440 348 282 230 192 156 116 83 57 33 16 8 4 0
CI = confidence interval; HR = hazard ratio; OS = overall survival.